|Bid||25.00 x 3100|
|Ask||27.38 x 1100|
|Day's Range||25.25 - 26.36|
|52 Week Range||15.21 - 32.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 16, 2016 - Mar 21, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.00|
PolarityTE, Inc. (COOL) today announced the appointment of Howard Hechler as Chief Business Officer. Mr. Hechler will lead the Company’s M&A and partnering efforts, as well as work with Executive Management to develop and execute the Company’s commercialization strategy. Mr. Hechler has nearly 15 years of life-sciences experience in Pharma, Medical Devices, and Diagnostics. Most recently, he was Senior Director of Corporate Development at Smith & Nephew. Previously, he was Senior Director of Strategy and Portfolio Development at Medtronic. Before that, he worked in Commercial Strategy and M&A roles for various pharma, incubator, and consulting firms, including Mallinckrodt, XL TechGroup, and Campbell Alliance. Mr. Hechler has a B.A. from Harvard University, as well as an MBA and Juris Doctorate, both from the University of Virginia.
PolarityTE, Inc. (COOL) today announced the appointment of Rich Haerle as Vice President of Investor Relations and Strategy. Mr. Haerle will lead the Company’s investor relations and corporate engagement with the investor community based in New York City. Mr. Haerle will also work with Executive Management to develop and execute the Company’s business strategy and corporate messaging.
PolarityTE™, Inc. (COOL) announced the acquisition of a preclinical biomedical research facility in order to accelerate research and development of PolarityTE pipeline products. The facility is an already fully-functional, operational and profitable contract research organization (CRO) which is regulated and compliant under both Good Laboratory Practices (GLP) and United States Department of Agriculture (USDA) standards. “This purchase was a strategically pragmatic way to further expand our already robust research and development programs, and integrate a new arm of the company—PolarityRD—which will function as an advanced CRO to help drive the field of biotechnology to deliver on the promise of exciting emerging technology,” said Denver Lough MD, PhD, CEO and Chairman of PolarityTE.
PolarityTE, Inc. (COOL) announced today that it is growing its commercial presence by hiring dedicated sales representatives on the East Coast to accelerate the regional market release of SkinTE™. SkinTE is a human cellular and tissue-based product derived from a patient’s own skin, and is intended for the repair, reconstruction, and replacement of skin tissue. SkinTE results have shown the regeneration of full-thickness (epidermis, dermis and hypodermis), functionally-polarized skin with all the appendages including hair and glands.
SALT LAKE CITY, May 01, 2018-- PolarityTE™, Inc. announced results demonstrating that the Company’ s autologous bone product in development, OsteoTE TM, regenerated complex, hierarchically-organized, corticocancellous ...
SALT LAKE CITY, April 26, 2018-- PolarityTE, Inc. today announced attendance and participation in the Symposium on Advanced Wound Care Spring Wound Healing Society meeting being held in Charlotte, North ...
On November 1, 2017, NASDAQ notified the Company that it did not comply with the independent director requirement for continued listing on The Nasdaq Capital Market set forth in Listing Rules 5605(b)(1) and 5605(c)(2). The Rule requires that a majority of the directors comprising the Company’s Board of Directors be considered “independent,” as defined under the Rule.
PolarityTE, Inc. (COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, announced today that Willie Bogan, former Corporate Secretary of McKesson Corporation, has joined the Company’s Board of Directors. “With PolarityTE now just a little over one year old, we have seen tremendous growth and evolving momentum across all fronts of the Company. From rapid translation of R&D, to the buildout of our new and fully-scalable manufacturing facility, and now most importantly, tangible clinical outcomes in patients treated with our commercial SkinTE tissue product, PolarityTE is continuing to expand its commercial departments.
PolarityTE, Inc. (COOL) today announced continued success with SkinTE during its limited-market release across a variety of conditions, including burns, wounds, surgical reconstruction and the replacement of skin grafts. In the end, however, the most important outcome is the impact on the patient’s life,” said Dr. Denver Lough, CEO of PolarityTE. Among the outcomes observed are a SkinTE case involving a patient who suffered from a large chronic leg wound for multiple years.
|Initiated||Cantor Fitzgerald : to Overweight||2/15/2018|
|Downgrade||Ascendiant : to Neutral||1/15/2013|
|Downgrade||Sidoti & Co. : to Neutral||1/15/2013|
|Downgrade||Needham : to Hold||9/11/2012|
Industry : Biotechnology
Full Time Employees : 33
PolarityTE, Inc. operates as commercial-stage biotechnology and regenerative biomaterials company in the United States. The company focuses on discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its PolarityTE platform would be able to provide transform tissue regeneration, including potential regeneration of multiple tissue substrates, such as skin, bone, muscle, fat, cartilage, nerves, and blood vessels, as well as neural elements, solid and hollow organ composite tissue systems. The company is headquartered in Salt Lake City, Utah.